KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Assets Average (2016 - 2025)

Regeneron Pharmaceuticals has reported Assets Average over the past 16 years, most recently at $40.4 billion for Q4 2025.

  • Quarterly results put Assets Average at $40.4 billion for Q4 2025, up 7.35% from a year ago — trailing twelve months through Dec 2025 was $40.4 billion (up 7.35% YoY), and the annual figure for FY2025 was $39.2 billion, up 10.56%.
  • Assets Average for Q4 2025 was $40.4 billion at Regeneron Pharmaceuticals, up from $39.2 billion in the prior quarter.
  • Over the last five years, Assets Average for REGN hit a ceiling of $40.4 billion in Q4 2025 and a floor of $17.5 billion in Q1 2021.
  • Median Assets Average over the past 5 years was $30.9 billion (2023), compared with a mean of $30.8 billion.
  • Biggest five-year swings in Assets Average: surged 48.23% in 2022 and later grew 6.61% in 2025.
  • Regeneron Pharmaceuticals' Assets Average stood at $24.6 billion in 2021, then rose by 15.86% to $28.4 billion in 2022, then grew by 14.68% to $32.6 billion in 2023, then rose by 15.26% to $37.6 billion in 2024, then increased by 7.35% to $40.4 billion in 2025.
  • The last three reported values for Assets Average were $40.4 billion (Q4 2025), $39.2 billion (Q3 2025), and $37.9 billion (Q2 2025) per Business Quant data.